Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM5UWH3)

Drug Name
PMID22911925C2 Drug Info
Synonyms compound 37 [PMID: 22468684]; GTPL6950; BDBM50397703; 0K9
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Clinical trial [1]
Cross-matching ID
PubChem CID
60202321
TTD Drug ID
DM5UWH3

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Beta-secretase (BACE) TT8JRS7 NOUNIPROTAC Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Beta-secretase (BACE) DTT BACE 5.928 4.638 6.443 5.3
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Beta-secretase (BACE) DTT NO-GeName 6.98E-04 1.03 2.84
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Design and synthesis of potent, orally efficacious hydroxyethylamine derived beta-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem. 2012 Nov 8;55(21):9025-44.
2 Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived beta-secretase inhibitors. J Pharmacol Exp Ther. 2012 Nov;343(2):460-7.